Learn how to order either FLEXBUMIN or BUMINATE [Albumin (Human)],
5% and 25% Solutions today.
More >
FLEXBUMIN 25% [Albumin (Human)], 25% Solution Versus Human Albumin in Glass Containers
FLEXBUMIN
shatter proof container eliminates safety concerns from glass breakage. This chart compares
flexible containers to glass and summarizes the major attributes and
advantages of using a flexible container.
| Attributes of FLEXBUMIN vs Albumin in a Glass Container | ||
Container Attribute |
FLEXBUMIN |
Glass-container Albumin |
Breakable |
No Risk of Glass Breakage |
Glass breakage possible |
Administration Set |
Infusion Set with 15-micron filter |
Vented Infusion Set with 15-micron filter |
Storage Space1 |
Shipper Carton (7 x 15 x 20.5 cm) 60% Less – (24) 50 mL or 55% Less – (12) 100 mL |
(24) 50 mL Box (15.5 x 21 x 18.5 cm) (12) 100 mL Box (12.2 x 17.5 x 22.3 cm) |
Weight1 |
(40% less than glass) 50 mL = 66 g/bag 100 mL = 120 g/bag |
50 mL = 113 g 100 mL = 196 g |
Open Container/Closed Container2,3,4 |
Closed Container2,4 |
Open Container3,4 |
Latex5 |
Contains no latex |
Some stoppers contain latex |
Coring of Stopper |
(no stopper) |
Risk |
PVC or DEHA5 |
Does not contain |
Not Applicable |
FLEXBUMIN 25% [Albumin (Human)]
FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. FLEXBUMIN 25% is indicated for hypovolemia, hypoalbuminemia due to general causes, burns, adult respiratory distress syndrome (ARDS), and nephrosis, and for use during or prior to cardiopulmonary bypass surgery, and hemolytic disease of the newborn (HDN).
Important Risk Information for FLEXBUMIN 25%
FLEXBUMIN 25% is contraindicated in patients with cardiac failure, in patients with severe anemia and in patients with a history of allergic reactions to human albumin.
Do not use if turbid. Do not begin administration more than 4 hours after the container has been entered.
Do not use Sterile Water for Injection as a diluent. There exists a risk of potentially fatal hemolysis and acute renal failure from the inappropriate use of Sterile Water for Injection as a diluent for FLEXBUMIN 25%. Acceptable diluents include 0.9% Sodium Chloride or 5% Dextrose in Water.
FLEXBUMIN 25% is made from pooled human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt–Jakob disease (CJD) agent.
FLEXBUMIN 25% must be administered intravenously at a rate not to exceed 1 mL/min to patients with normal blood volume, due to the risk of developing circulatory overload and pulmonary edema.
When 25% albumin is infused, a rise in blood pressure necessitates careful observation to detect and treat severed blood vessels that may not have bled at a lower blood pressure.
Adverse reactions to FLEXBUMIN 25% are extremely rare, although nausea, fever, chills or urticaria may occasionally occur.
CAUTION: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is complete.
Please see Preparation for Administration for FLEXBUMIN 25% in the Prescribing Information.
Please review the FLEXBUMIN 25% [Albumin (Human)] Prescribing Information for full prescribing details.
BUMINATE 5% [Albumin (Human)], USP, 5% Solution
BUMINATE 5% is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. BUMINATE 5% is indicated in hypovolemia, hypoalbuminemia, burns, and cardiopulmonary bypass surgery.
Please see Important Risk Information for BUMINATE 5% and Full Prescribing Information.
BUMINATE 25% [Albumin (Human)], USP, 25% Solution
BUMINATE 25% is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. BUMINATE 25% is indicated in hypovolemia, hypoalbuminemia, burns, adult respiratory distress syndrome (ARDS), nephrosis, cardiopulmonary bypass surgery, and hemolytic disease of the newborn (HDN).
Please see Important Risk Information for BUMINATE 25% and Full Prescribing Information.
- Storage space and weight comparison. Data on file. Baxter Healthcare Corporation.
- FLEXBUMIN 25% Albumin (Human) [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2009.
- BUMINATE 25% [Albumin (Human)] Prescribing Information. Westlake Village, CA: Baxter Healthcare Corporation; September 2009.
- Lyles A. et al. Drug delivery systems role in preventing central line-associated bacteraemia: an international perspective. EJHP Practice. 2009; 15(5)39-44
- GALAXY Container Components. Data on File. Baxter Healthcare Corporation.
